Free tool
FAERS Monitor: Zipsor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022202 or its brand name (Zipsor, Diclofenac Potassium). Reports on generic versions are filed under their own applications.
Reports
9,031
Serious
8,021
89% of reports
Hospitalization
4,738
Death reported
4,371
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rheumatoid arthritis2,666
- fatigue2,566
- rash2,500
- drug ineffective2,493
- systemic lupus erythematosus2,492
- pain2,485
- off label use2,475
- joint swelling2,418
- wound2,384
- pemphigus2,316
- glossodynia2,293
- synovitis2,291
- infusion related reaction2,266
- hand deformity2,259
- pericarditis2,248
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 9 |
| 2006 | 59 |
| 2007 | 9 |
| 2008 | 16 |
| 2009 | 15 |
| 2010 | 23 |
| 2011 | 73 |
| 2012 | 51 |
| 2013 | 55 |
| 2014 | 64 |
| 2015 | 132 |
| 2016 | 354 |
| 2017 | 249 |
| 2018 | 368 |
| 2019 | 426 |
| 2020 | 425 |
| 2021 | 419 |
| 2022 | 637 |
| 2023 | 807 |
| 2024 | 2,030 |
| 2025 | 1,893 |
| 2026 | 913 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,128 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 2,316 | 529.2 | 508.4 | 995,232 |
| hand deformitySignal | 2,259 | 484.2 | 465.1 | 902,124 |
| pericarditisSignal | 2,248 | 359.6 | 345.7 | 696,659 |
| synovitisSignal | 2,291 | 338.8 | 325.9 | 673,912 |
| glossodyniaSignal | 2,293 | 265.6 | 255.7 | 543,022 |
| woundSignal | 2,384 | 217.1 | 209.3 | 469,439 |
| systemic lupus erythematosusSignal | 2,492 | 175.8 | 169.7 | 403,210 |
| infusion related reactionSignal | 2,266 | 82.4 | 79.4 | 176,460 |
| rheumatoid arthritisSignal | 2,666 | 56.0 | 54.2 | 141,291 |
| joint swellingSignal | 2,418 | 47.6 | 46.0 | 108,646 |
| rashSignal | 2,500 | 13.4 | 13.0 | 29,185 |
| painSignal | 2,485 | 9.5 | 9.1 | 19,269 |
| fatigueSignal | 2,566 | 7.7 | 7.4 | 15,471 |
| off label useSignal | 2,475 | 6.6 | 6.4 | 12,227 |
| drug ineffectiveSignal | 2,493 | 4.4 | 4.3 | 7,001 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.